Mark Connors (physician)
 | The topic of this article may not meet Wikitia's general notability guideline. |
Mark Connors | |
|---|---|
| Alma mater | Temple University (BA, MD) |
| Known for | Research on Long-term nonprogressors |
| Scientific career | |
| Fields | Immunology |
Mark Connors is a researcher at the National Institutes of Health (NIH) specializing in HIV/AIDS. He serves as the Chief of the HIV-Specific Immunity Section at the National Institute of Allergy and Infectious Diseases (NIAID), where he oversees efforts to understand and enhance the immune response to HIV and other viruses. His research focuses on identifying effective immune responses to viruses to aid in the development of vaccines and immunotherapies.[1]
Career and Research
Mark Connors received his medical degree from Temple University, followed by pediatric training at Tufts Medical Center, and infectious diseases training at NIAID and the Children's Hospital of Philadelphia.ining at NIAID and the Children's Hospital of Philadelphia. He has been with the NIH since 1989, initially studying the immune response to respiratory viruses before shifting his focus to HIV in 1994. He has studied the immunologic control of HIV, particularly in Long-term nonprogressor or "elite controllers" who can control HIV without antiretroviral therapy. His research on this group has provided insights into effective immune responses to HIV and potential strategies for HIV treatment and prevention.[1]
In addition to his work on the cellular immune response to HIV, Connors has focused on the antibody response. He identified patients with broad antibody responses to HIV and isolated monoclonal antibodies, such as 10E8, 35O22, and N6, that target sites of vulnerability on the HIV envelope protein. The antibody N6, for example, can neutralize nearly all HIV strains.[2][3][4] This research may inform the development of HIV treatments and vaccines, as these antibodies target critical parts of the virus that attach to immune cells.
Connors' work contributes to the understanding of HIV and has implications for broader immunological research and public health.
References
- ↑ 1.0 1.1 "Mark Connors, M.D." NIAID. National Institutes of Health. 12 July 2022.
- ↑ Huang, Jinghe; Kang, Byong H.; Pancera, Marie; Lee, Jeong Hyun; et al. (November 2014). "Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface". Nature. 515 (7525): 138–142. Bibcode:2014Natur.515..138H. doi:10.1038/nature13601. ISSN 0028-0836. PMC 4224615. PMID 25186731.
- ↑ "NIH Scientists Identify Potent Antibody that Neutralizes Nearly All HIV Strains". Clinical Info. HIV.gov. 18 November 2016.
- ↑ Huang, Jinghe; Ofek, Gilad; Laub, Leo; Louder, Mark K.; et al. (2012-11-15). "Broad and potent neutralization of HIV-1 by a gp41-specific human antibody". Nature. 491 (7424): 406–412. Bibcode:2012Natur.491..406H. doi:10.1038/nature11544. ISSN 0028-0836. PMC 4854285. PMID 23151583.
External links
This article "Mark Connors (physician)" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.